Warning: file_get_contents(https://multipass.sense-studios.com/check_token/-1?url=%2Fcontent%2Fconference-reports%2F2019-07-30-092507%2F&agent=CCBot%2F2.0+%28https%3A%2F%2Fcommoncrawl.org%2Ffaq%2F%29&name=dev.mc.sense-studios.com&ip=34.225.194.102&categories=Conference+Report+Article%7CEpilepsy%7CNeurology%7CAAN+2019): failed to open stream: HTTP request failed! HTTP/1.1 500 Internal Server Error in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/header-tokenaccess.php on line 114

Notice: Trying to get property 'status' of non-object in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/header-tokenaccess.php on line 117

Notice: Trying to get property 'access_type' of non-object in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/header-tokenaccess.php on line 123
Long term safety of diazepam nasal spray - Medical Conferences

Home > Neurology > AAN 2019 > Epilepsy > Long term safety of diazepam nasal spray

Long term safety of diazepam nasal spray


Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 138

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 138

Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 174

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 174

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 175
Conference
AAN 2019
An interim-analysis of an open-label trial showed that diazepam nasal spray is safe and well tolerated in epilepsy patients with frequent breakthrough seizures or acute repetitive seizures. Adverse events were generally mild or moderate in severity, and mostly unrelated to treatment [1].

Of 121 enrolled patients thus far, 109 were included in the safety analysis. Their median age was 14 years. Diazepam nasal spray was administered as needed to treat bouts of diagnosed seizures over a 12-month period. Doses were 5, 10, 15, or 20 mg based on age and body weight. A total of 1,585 seizure episodes were treated with diazepam nasal spray (1 to >40 doses). A single dose adequately controlled seizures in 92% of seizure episodes. Overall, 67 patients had at least one adverse event. A total of 19 patients had treatment-related adverse events, the most frequent of which was nasal discomfort (n=7); 18 patients had 30 serious adverse events that were not treatment-related.

1. Sperling M,et al. AAN 2019, P1.5-028.



Posted on